4{[(5-phenyl-1 2,4-oxadiazol-3-yl)methyl]sulfonyl}phenethylamine | 391671-80-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4{[(5-phenyl-1 2,4-oxadiazol-3-yl)methyl]sulfonyl}phenethylamine
• 英文别名: 2-[4-[(5-Phenyl-1,2,4-oxadiazol-3-yl)methylsulfonyl]phenyl]ethanamine
• CAS: 391671-80-0
• 化学式: C₁₇H₁₇N₃O₃S
• 分子量: 343.406
• InChiKey: BUSLOENGAAJZLZ-UHFFFAOYSA-N

物化性质

• 沸点：
  584.2±60.0 °C(Predicted)
• 密度：
  1.306±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  108
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• Substituted arylsulfides, arylsulfoxides and arylsulfones as beta-3 adrenergic receptor agonists
  申请人：American Home Products Corporation

  公开号：US20020040023A1

  公开（公告）日：2002-04-04

  This invention provides compounds of Formula I having the structure 1 wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , Y, Z, m, n, 2 and are as defined hereinbefore or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination; and are particularly useful in the treatment or inhibition of type 11 diabetes.

  本发明提供了具有以下结构式的I型化合物： 1 其中R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , Y, Z, m, n, 2 以及前述定义的 pharmaceutically acceptable salt，它们在治疗或抑制与胰岛素抵抗或高血糖相关的代谢紊乱（通常与肥胖或葡萄糖不耐受有关）、动脉粥样硬化、胃肠疾病、神经源性炎症、青光眼、眼压升高和频繁排尿方面非常有用；它们在治疗或抑制2型糖尿病方面特别有用。
• US6458817B1
  申请人：——

  公开号：US6458817B1

  公开（公告）日：2002-10-01
• [EN] SUBSTITUTED ARYLSULFIDES, ARYLSULFOXIDES AND ARYLSULFONES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS<br/>[FR] ARYLSULFURES, ARYLSULFOXYDES ET ARYLSULFONES SUBSTITUES, UTILES EN TANT QU'AGONISTES DU RECEPTEUR ADRENERGIQUE BETA-3
  申请人：AMERICAN HOME PROD

  公开号：WO2002006250A1

  公开（公告）日：2002-01-24

  This invention provides compounds of Formula I having the structure wherein R1, R2, R3, R4, R5, R6, Y, Z, m, n, are as defined hereinbefore or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes.